923032-57-9

Basic information

• Product Name: 1-Allylcyclopropanesulfonic Acid Potassium Salt
• Synonyms: 1-Allylcyclopropanesulfonic Acid Potassium Salt;1-(2-Propen-1-yl)-cyclopropanesulfonic Acid PotassiuM Salt;potassium 1-allylcyclopropane-1-sulfonate
• CAS NO: 923032-57-9
• Molecular Formula: C6H9KO3S
• Molecular Weight: 200.29716
• Product Categories: Intermediates;Miscellaneous Reagents;Sulfur & Selenium Compounds
• Mol File: 923032-57-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Solubility: Water
• CAS DataBase Reference: 1-Allylcyclopropanesulfonic Acid Potassium Salt(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Allylcyclopropanesulfonic Acid Potassium Salt(923032-57-9)
• EPA Substance Registry System: 1-Allylcyclopropanesulfonic Acid Potassium Salt(923032-57-9)

Safety Data

• Hazardous Substances Data: 923032-57-9(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1/C6H10O3S.K/c1-2-3-6(4-5-6)10(7,8)9;/h2H,1,3-5H2,(H,7,8,9);/q;+1/p-1/rC6H9KO3S/c1-2-3-6(4-5-6)11(8,9)10-7/h2H,1,3-5H2

Upstream product

• 923032-53-5 butyl 1-methylcyclopropane-1-sulfonate 
• 923032-56-8 butyl 1-allylcyclopropane-1-sulfonate 

Downstream Products

• 923032-59-1 1-allylcyclopropane-1-sulfonyl chloride 
• 923032-61-5 1-allyl-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl)cyclopropane-1-sulfonamide 
• 923032-78-4 1-allyl-cyclopropanesulfonic acid [3,4,6-trifluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-amide 

Relevant articles and documents

BIOMARKERS FOR DETERMINING EFFECTIVE RESPONSE OF TREATMENTS OF HEPATOCELLULAR CARCINOMA (HCC) PATIENTS

This invention is directed to the use of one or more biomarkers defined as KRAS or NRAS gene for predicting the pharmaceutical efficacy or clinical response of MEK protein kinase inhibitor and/or Sorafenib or Regorafenib to be administred to a Hepatocellu

NOVEL 6-ARYLAMINO PYRIDONE SULFONAMIDES AND 6-ARYLAMINO PYRAZINONE SULFONAMIDES AS MEK INHIBITORS

The invention provides novel substituted 6-arylamino pyridone sulfonamides and 6 arylamino pyrazinone sulfonamides represented by Formula I, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans